- €46.17bn
- €78.52bn
- €45.58bn
Europe Research Roundup: Antofagasta, Danske Bank, Munich Re
Europe Research Roundup: Antofagasta, Danske Bank, Munich Re
Brief: Bayer's Asundexian stroke trial shows fewer ischemic events, no bleeding risk – NEJM
Ocular Therapeutix rises as new eye drug shows longer disease control
Bayer US head says tariffs will not affect its 2026 forecasts
Evotec vows to further engage with investor MAK, who demanded change
Brief: UK's MHRA Approves Bayer's Sevabertinib To Treat Adults With HER2-Positive Lung Cancer
Media: Bayer weighs U.S. pharma expansion as turnaround picks up speed - WSJ
Media: Europe must pay more for medicines, says Bayer - FT
Brief: Bayer - Askbio Announces Completion Of Enrollment In Phase 2 Clinical Trial Of AB-1002
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Bayer Appoints Nelson Ambrogio To Lead U.S. Pharmaceuticals Business
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Bayer AG - Kerendia Approved In EU For New Indication
Social-media verdicts preview AI legal hazards
German chemical union delays wage hikes as war worsens business outlook (updated)
"Crisis"-hit German chemical sector holds off on wage hikes until early-2027
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions